On July 22, 2024, XTL Biopharmaceuticals Ltd. held a meeting where shareholders approved key proposals including the appointment of new auditors and re-election of board members. Additionally, they agreed to acquire The Social Proxy Ltd., involving a cash payment of $430,000 and issuance of equity representing 44.6% of the company.